Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

34.28USD
27 Feb 2017
Change (% chg)

$0.02 (+0.06%)
Prev Close
$34.26
Open
$34.23
Day's High
$34.46
Day's Low
$34.16
Volume
21,830,284
Avg. Vol
27,438,677
52-wk High
$37.39
52-wk Low
$28.74

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $204,030.20
Shares Outstanding(Mil.): 5,951.87
Dividend: 0.32
Yield (%): 3.73

Financials

  PFE Industry Sector
P/E (TTM): 29.40 29.27 29.99
EPS (TTM): 1.17 -- --
ROI: 5.20 13.52 13.04
ROE: 11.58 14.41 14.18

Merck KGaA, Pfizer get priority review for bladder cancer drug

FRANKFURT German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek to widen the use of immunotherapy drug avelumab to include bladder cancer.

7:42am EST

Merck KGaA, Pfizer get priority review for bladder cancer drug

FRANKFURT, Feb 28 German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek to widen the use of immunotherapy drug avelumab to include bladder cancer.

7:38am EST

BRIEF-Pfizer says FDA accepts Biologics License Application for Avelumab for priority review

* Pfizer Inc - FDA has set a prescription drug user fee act (PDUFA) target action date of august 27, 2017, for Avelumab in this indication

7:17am EST

Pfizer subpoenaed in U.S. over patient assistance plans

Pfizer Inc said it received subpoenas from the U.S. Attorney's Office for the District of Massachusetts related to its support for organizations that provide financial help to Medicare patients.

Feb 27 2017

Pfizer subpoenaed in U.S. over patient assistance plans

Pfizer Inc said it received subpoenas from the U.S. Attorney's Office for the District of Massachusetts related to its support for organizations that provide financial help to Medicare patients.

Feb 24 2017

UPDATE 1-Pfizer subpoenaed in U.S. over patient assistance plans

Feb 24 Pfizer Inc said it received subpoenas from the U.S. Attorney's Office for the District of Massachusetts related to its support for organizations that provide financial help to Medicare patients.

Feb 24 2017

BRIEF-Ronald Blaylock elected to Pfizer's board of directors

* Blaylock was also appointed to corporate governance and science and technology committees of Pfizer's board Source text for Eikon: Further company coverage:

Feb 23 2017

BRIEF-Pfizer to cancel listing in the United Kingdom

* Applied to United Kingdom Listing Authority to cancel standard listing of company's common stock

Feb 22 2017

BRIEF-Pfizer said SIX swiss exchange approved delisting of its shares

* Said six swiss exchange approved its application to delist its shares from the six swiss exchange Further company coverage: (Reporting by Silke Koltrowitz)

Feb 22 2017

BRIEF-Momenta Pharmaceuticals announces FDA warning letter to contracted Glatopa

* Momenta Pharmaceuticals announces FDA warning letter to contracted glatopa (glatiramer acetate injection) fill/finish manufacturer

Feb 17 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $122.40 --
Novartis AG (NOVN.S) CHF78.05 +0.20
Merck & Co., Inc. (MRK.N) $65.85 --
Roche Holding Ltd. (ROG.S) CHF243.50 -0.10
Roche Holding Ltd. (RO.S) CHF246.20 -0.30
Abbott Laboratories (ABT.N) $45.46 --
Bayer AG (BAYGn.DE) €104.10 -0.20
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €80.89 +0.46
AstraZeneca plc (AZN.L) 4,672.50 +64.00

Earnings vs. Estimates